Iovance Biotherapeutics (IOVA)

Executive Summary

Iovance Biotherapeutics is a commercial-stage biotechnology company pioneering tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. In February 2024, the company achieved FDA accelerated approval of Amtagvi™ (lifileucel) for advanced melanoma, marking the first-ever approved TIL therapy and establishing a new treatment paradigm. Iovance is expanding its platform with a robust pipeline targeting multiple solid tumors, including non-small cell lung cancer (NSCLC), endometrial cancer, soft tissue sarcoma, and others. Key programs include a Phase 3 trial evaluating lifileucel plus pembrolizumab in previously untreated metastatic melanoma, and Phase 2 studies in endometrial cancer and cutaneous squamous cell carcinoma. The company is also developing next-generation therapies such as IOV-3001, a genetically modified TIL product designed to enhance persistence and efficacy. With a validated platform and growing commercial presence, Iovance is well-positioned to expand TIL therapy into new indications. Upcoming catalysts include data readouts from pivotal trials, potential label expansions, and progress in earlier-stage pipeline assets. The company's strong intellectual property and manufacturing capabilities support its leadership in cell therapy for solid tumors.

Upcoming Catalysts (preview)

• H1 2027Lifileucel Phase 3 data in metastatic melanoma (NCT05727904)80% success
• H2 2026Lifileucel Phase 2 data in endometrial cancer (NCT06481592)60% success
• H1 2027IOV-3001 Phase 1/2 initial data in melanoma (NCT06940739)40% success